Dr. Ralph Brückner has a strong interest for the interaction of chemistry with biological systems that has lead him through an exciting journey from Medicinal Chemistry to modern Hygiene. He has achieved his PHD at the university of Würzburg on the metabolic fate and neurotoxic behaviour of (14C)TaClo, an endogenously formed ß-carbolin. As post doc he moved to the research Center Jülich where he established one of the first hypenations of ion chromatography with mass spectrometry for the elucidation of Krebs-cyle metabolites in bacteria. From there he received a call to follow the new team of medicinal chemistry department of Boehringer Ingelheim in Vienna (Austria). As head of laboratory he was reponsible for PK/PD in the thrilling field of oncology for 8 years. Since 2016 he works within the HECOSOL GmbH as head of R&D on the development of antimicrobial surfaces in sensitive areas of the medical sector and the food industry. The intention is to reduce hospital acquired infection diseases by a permanent reduction of pathogenic germs.

ADME, Drug Discovery

Senior Clinical Operations Team Lead in global multi-regional trials responsible for resource management and clinical team performance, key performance indicatior adherence and overal study or program control. Clinical trial experience covers Phase II-IV trials in such fields as rheumatology, oncology, cardiology, pulmonology, neurology, endocrinology, infectious diseases and surgery

Global clinical trial management, Quality assurance

Biologist and pharmacologist , biochemist by training , with a Master in Science (Doctor in Biology) from the University of Florence, Italy , and a PhD in Pharmacology from the University of Toulouse, France, 1997, Cristina Cosi has an extensive working experience in the Neuroscience research field, mostly in industry at Pierre Fabre, France, but also in academic environments, in Italy , University of Florence and Verona, and US, NIH. She has focused her career on the understanding of neurodegenerative processes and mechanisms of neuronal plasticity in order to find medications that might be beneficial against neurodegenerative and neurodevelopmental diseases and pain. She has done pioneering work in the poly(ADP-ribose) polymerase (PARP) inhibitors preclinical research field, by showing evidence of the neuroprotective activity of these compounds, for the first time. She has contributed to the discovery and development of neurotrophins receptors TRKA/B inhibitors as potential analgesics and D3 antagonists/5-HT1A agonists as potential antipsychotics.

Pharmacology and Neuroscience

Vuong Trieu, Ph.D. is the founder and chairman of Oncotelic and was appointed to the Company’s Board and to serve as Chairman of the Board and CEO of Mateon in connection with the Merger with Oncotelic. Dr. Trieu is an expert is drug repositioning with several high profile successes including Abraxane and Cynviloq- both are billion dollar drugs. He is leading Mateon effort to become the next generation pharmaceutical by leveraging AI data analytics to create a high value pipeline. You don’t know what you don’t know- but there is no excuse for not knowing.

Nanomedicine and Oncology

Dr. Kinjal Pragnesh Solanki has completed her PhD in 2017 from Bhagwant University, India and M.Pharm from Ganpat University, India. She is the Associate Professor in Shankersinh Vaghela Bapu Institute of Pharmacy, India. She has published more than 25 papers in reputed journals and has been advisory member in many professional bodies.

Pharmacology and Toxicology

Dr. Ralph Brückner has a strong interest for the interaction of chemistry with biological systems that has lead him through an exciting journey from Medicinal Chemistry to modern Hygiene. He has achieved his PHD at the university of Würzburg on the metabolic fate and neurotoxic behaviour of (14C)TaClo, an endogenously formed ß-carbolin. As post doc he moved to the research Center Jülich where he established one of the first hypenations of ion chromatography with mass spectrometry for the elucidation of Krebs-cyle metabolites in bacteria. From there he received a call to follow the new team of medicinal chemistry department of Boehringer Ingelheim in Vienna (Austria). As head of laboratory he was reponsible for PK/PD in the thrilling field of oncology for 8 years. Since 2016 he works within the HECOSOL GmbH as head of R&D on the development of antimicrobial surfaces in sensitive areas of the medical sector and the food industry. The intention is to reduce hospital acquired infection diseases by a permanent reduction of pathogenic germs.

ADME, Drug Discovery

Mr. Sinha received his Bachelors of Science (BS) and Master of Science (MS) degrees in Bacteriology / Natural Science from the University of Wisconsin – Madison, Wisconsin, USA. He completed his Master’s in Business Administration (MBA) from the New York Institute of Technology, New York, USA. Kuntal Sinha has been in the Pharmaceutical industry for over 25 years. His experience over the years have spanned within the Contract Research Organization (CRO) and pharmaceutical companies. At Covance, Mr. Sinha’s responsibility included research supporting Metabolic Chemistry and Drug Metabolism Since 2016, Mr. Sinha has been managing the activities associated with pharmacovigilance and clinical trial safety and serves as an advisory / consultative capacity in compliance related safety matters. More recently, Mr. Sinha is Director at Alkermes within Clinical Quality Assurance group supporting pharmacovigilance, Medical Affairs and Commercial Organization on drug safety related to adverse events and product complaints.

Clinical Trails

Mr. Sinha received his Bachelors of Science (BS) and Master of Science (MS) degrees in Bacteriology / Natural Science from the University of Wisconsin – Madison, Wisconsin, USA. He completed his Master’s in Business Administration (MBA) from the New York Institute of Technology, New York, USA. Kuntal Sinha has been in the Pharmaceutical industry for over 25 years. His experience over the years have spanned within the Contract Research Organization (CRO) and pharmaceutical companies. At Covance, Mr. Sinha’s responsibility included research supporting Metabolic Chemistry and Drug Metabolism Since 2016, Mr. Sinha has been managing the activities associated with pharmacovigilance and clinical trial safety and serves as an advisory / consultative capacity in compliance related safety matters. More recently, Mr. Sinha is Director at Alkermes within Clinical Quality Assurance group supporting pharmacovigilance, Medical Affairs and Commercial Organization on drug safety related to adverse events and product complaints.

Clinical Trails

Physician with more than 20 years of experience in clinical development and pharmacovigilance. After working for several years as Vice President and Global Head of drug safety & risk management for Lupin, she founded Clinexel Life Sciences Pvt Limited, that provides consulting and operations services to pharma companies. Deepa has rich experience in conceptualizing innovative products, developing efficient 505b(2) clinic- regulatory strategies for biosimilar and hybrid applications. She was a key member for clinical development and safety monitoring of biosimilars & NCEs in 3 companies. She participated in regulatory meetings with FDA, EMA, rapporteurs and CHMP to discuss the clinical development plans, risk management plans, post marketing data collection required for hybrid applications and requirements of post marketing studies. She has successfully led a consortium of leading generic companies including Teva, Lupin, Sandoz, Alvogen, Mylan, Generis and Gedeon Richter in Europe to conduct post authorization clinical studies imposed as a condition of marketing authorization for a generic product. After successfully completing these studies, results were published in peer reviewed journals.

Pharmacovigilance

M.D., Medical Doctor/ Physician, graduated from Tehran university, School of Medicine with honor. He studied in neurosurgery ward and graduated with a score with thesis on Meningioma Brain Tumour during 6 years. With continuing my practice with special consideration on psychosomatic disorders, He completed many post graduate courses on health psychology, addiction medicine, sexual disorders therapy successfully. He passed many post graduate courses in Neuro, approved by Medical Sciences University. As well, He have been passed post graduate courses on Nutrition, Gastroenterology and herpetology, Obesity treatment and diabetes approved by Tehran University of Medical sciences. He is director of fatty liver and related metabolic disorders study among Iranian families since 2015 and currently publishing the results of our study and research about fatty liver and hyperlipidaemia, diabetes and nutrition as study director and clinician associate member of Iran Hepatitis Network. I am reviewer and associate editor of Hepatitis Monthly Journal and reviewer of journal of Clinical and Translational Herpetology. He is editorial board member of International Journal of Psychology and Neurosciences. He certified graduate, verified reviewer and certified mentor of Publons academy in the field of Clinical Medicine and Herpetology.

Published article in Metabolic disease pharmacology high indexed journal